A six-year-old girl with Snijders Blok-Campeau syndrome died in March 2025 during an experimental gene-editing treatment in China. Neuroscientist Zilong Qiu led the trial, which a hospital ethics committee had approved under a regulatory provision that did not require national-level approval. The death was not disclosed to Qiu’s superiors, and the child was left out of a report published in Nature. The girl’s parents reportedly paid more than $800,000 toward the project but were not told about its risks.
A government investigation found that Qiu’s team had ignored safety concerns raised by earlier primate tests. The girl’s father said the family had not understood how dangerous or unusual the trial arrangements were. Shanghai authorities fired Qiu from his university-affiliated post, barred him from scientific projects for five years, and listed him for serious research-integrity violations. Another team member received the same sanctions, while other researchers connected to the hospital were disciplined. The trial was abandoned after the child’s death; the case has raised concerns about oversight, informed consent, and the handling of experimental gene therapies.
Summary generated by AI from the linked article. hn.today is not affiliated with Hacker News or Y Combinator.